Active Ingredient History

NOW
  • Now
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration, diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$746.5400 - $1950.0000

Australia

$764.8645
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

fab-12 variant y0317 | lka651 | lucentis | ranibizimumab | ranibizumab | rfb002 | rg-3645 | rhufab | rhufab v2

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue